Onychomycosis Treatment Market Size Share Value and Forecast 2024

Onychomycosis Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Onychomycosis Treatment Market&nbsp;is segmented By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis, Total Dystrophic Onychomycosis) By Treatment Type (Oral therapy, Topical Therapy, Photodynamic Therapy, CiclopiroxNail Lacquers, Others) By End User (Hospitals, Clinics, Others)&nbsp;and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

<h3>Market Overview</h3>

<blockquote>
Global Onychomycosis Treatment Market reached US$ YY&nbsp;million in 2023 and is expected to reach US$ YY&nbsp;million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
</blockquote>

Onychomycosis is an infection of the nail caused by fungi such as dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida species) in which 80% of the toenail infections are caused by dermatophytes (Trichophyton rubrum). Onychomycosis is classified clinically as distal and lateral subungual onychomycosis (DLSO), superficial white onychomycosis (SWO), proximal subungual onychomycosis (PSO), candidial onychomycosis and total dystrophic onychomycosis.

<h3>Market&nbsp;Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Type, Treatment Type, End User
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report &ndash; <a href="https://www.datamintelligence.com/download-sample/onychomycosis-treatment-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers &amp; Restraints</h3>

Rise in&nbsp; the prevalence of diabetes

Onychomycosis is a common fungal infection affecting a significant portion of the population worldwide. As awareness of the condition grows and diagnostic techniques improve, more cases are diagnosed, leading to an increased demand for treatments.

For instance, onychomycosis is more common in diabetics than non-diabetics, and diabetics are at greater risk of serious complications from onychomycosis. According to the International Diabetes Federation 2021, around 537 million adults (20-79 years) are living with diabetes, 1 in 10. This number is expected to rise to reach 643 million by 2030 and 783 million by 2045. This in turn is expected to aid in the growth onychomycosis treatment market.

Furthermore, global onychomycosis treatments are also driven by various other factors like a rise in the advancements in treatment options, a rise in the prevalence of fungal infections and others helping the market to grow during the forecast period.

Lack of awareness&nbsp;

The market for onychomycosis is hindered by a lack of awareness about the condition, leading to undiagnosed nail fungal infections. People often ignore symptoms like decolourization, thickening of nails, and separation from the nail bed, preventing treatment. This lack of awareness and the potential side effects of onychomycosis treatment drugs also contribute to the market&#39;s potential for future decline. Therefore, it is predicted that the market will suffer in the assessment period.

<h3>Segment Analysis</h3>

The global onychomycosis treatment market is segmented based on type, treatment type, end-user and region.

The oral therapy from the treatment type segment accounted for approximately 41.3% of the onychomycosis treatment&nbsp; market share

The oral therapy from the treatment type segment accounted for approximately 41.3%. The most commonly used oral drugs for the treatment of onychomycosis are griseofulvin, terbinafine, itraconazole and ketoconazole. The disadvantages of oral antifungal agents are, they require a longer treatment period and they have more side effects, e.g. terbinafine (Lamisil). This drug is taken daily for 8 weeks for fingernail fungus and 12 weeks for toenail fungus. The most frequent side effects of Lamisil are headache, gastrointestinal disturbance (diarrhoea and/or dyspepsia), rash and elevated liver enzymes.

<h3>Geographical Analysis</h3>

North America is estimated to hold about 40.4% of the total market share throughout the forecast period 

North America is estimated to hold about 40.4% of the total market share throughout the forecast period owing to factors like rising prevalence of onychomycosis in adults/elderly population and increasing awareness about safe and effective treatment in the region. Also, ongoing clinical trials, novel product launches and others help the region to have the highest market share during the forecast period.

For instance, in January 2024, Vanda Pharmaceuticals Inc. (Vanda) stated that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

<h3>Covid 19 Impact Analysis</h3>

The covid 19 pandemic had a significant impact on the onychomycosis market where before the COVID-19 pandemic, clinical examinations, dermoscopy, and mycological examinations were recommended for patients with suspected onychomycosis. As the pandemic spreads, non-urgent in-patient visits are postponed, and telemedicine may be used for diagnosis and treatment.&nbsp;

<h3>Competitive Landscape</h3>

The major global players in the market include Bausch Health Companies Inc., Novartis AG, Pfizer, Inc., Moberg Pharma AB, Bayer AG, Dr Reddy&rsquo;s Laboratories Ltd, Gladerma, Medimetriks Pharmaceuticals, Inc., Kaken Pharmaceuticals, Hahn Medical Systems among others.

<h3>Key Developments</h3>

<ul>
	<li>In February 2024, Moberg Pharma Abs marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals, launched sales of MOB-015 under the Terclara brand. The interest among pharmacies has been significant for Moberg Pharma&#39;s medication against nail fungus.</li>
	<li>In July 2022, Zydus Lifesciences subsidiary received approval from the US health regulator to market an antifungal Efinaconazole Topical solution. Zydus Worldwide DMCC received final approval from the US Food and Drug Administration (USFDA) to market the product. Efinaconazole is an antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global onychomycosis treatment market segmentation based on type, treatment type, end user and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analysing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of the onychomycosis treatment market level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global onychomycosis treatment market report would provide approximately 64 tables, 61 figures and 186 pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Type</li>
		<li>Snippet by Treatment Type&nbsp;</li>
		<li>Snippet by End User</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Rise in&nbsp; prevalence of diabetes</li>
				<li>Rise of advancements in treatment options</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Lack of awareness</li>
				<li>XX</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Patent Analysis</li>
		<li>PESTLE Analysis</li>
		<li>SWOT Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By&nbsp; Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Distal Subungual Onychomycosis*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">White Superficial Onychomycosis</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Proximal Subungual Onychomycosis</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Candida Onychomycosis</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Total Dystrophic Onychomycosis</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment Type</h3>

	<ol>
		<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type&nbsp;</li>
		<li>Market Attractiveness Index, By Treatment Type</li>
	</ol>

	<ol>
		<li>Oral therapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Topical Therapy</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Photodynamic Therapy</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">CiclopiroxNail Lacquers</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Others</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Clinics</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Others</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Bausch Health Companies Inc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Novartis AG</li>
		<li>Pfizer, Inc</li>
		<li>Moberg Pharma AB</li>
		<li>Bayer AG</li>
		<li>Dr. Reddy&rsquo;s Laboratories Ltd</li>
		<li>Gladerma</li>
		<li>Medimetriks Pharmaceuticals, Inc</li>
		<li>Kaken Pharmaceuticals</li>
		<li>Hahn Medical Systems&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Onychomycosis Treatment Market Value, By Type, 2023, 2027 &amp; 2031(US$ Million)

Table 2 Global Onychomycosis Treatment Market Value, By Treatment Type, 2023, 2027 &amp; 2031(US$ Million)

Table 3 Global Onychomycosis Treatment Market Value, By End User, 2023, 2027 &amp; 2031(US$ Million)

Table 4 Global Onychomycosis Treatment Market Value, By Region, 2023, 2027 &amp; 2031(US$ Million)

Table 5 Global Onychomycosis Treatment Market Value, By Type, 2023, 2027 &amp; 2031(US$ Million)

Table 6 Global Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 7 Global Onychomycosis Treatment Market Value, By Treatment Type, 2023, 2027 &amp; 2031(US$ Million)

Table 8 Global Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 9 Global Onychomycosis Treatment Market Value, By End User, 2023, 2027 &amp; 2031(US$ Million)

Table 10 Global Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 11 Global Onychomycosis Treatment Market Value, By Region, 2023, 2027 &amp; 2031(US$ Million)

Table 12 Global Onychomycosis Treatment Market Value, By Region, 2022-2031(US$ Million)

Table 13 North America Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 14 North America Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 15 North America Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 16 North America Onychomycosis Treatment Market Value, By Country, 2022-2031(US$ Million)

Table 17 South America Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 18 South America Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 19 South America Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 20 South America Onychomycosis Treatment Market Value, By Country, 2022-2031(US$ Million)

Table 21 Europe Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 22 Europe Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 23 Europe Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 24 Europe Onychomycosis Treatment Market Value, By Country, 2022-2031(US$ Million)

Table 25 Asia-Pacific Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 26 Asia-Pacific Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 27 Asia-Pacific Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 28 Asia-Pacific Onychomycosis Treatment Market Value, By Country, 2022-2031(US$ Million)

Table 29 Middle East &amp; Africa Onychomycosis Treatment Market Value, By Type, 2022-2031(US$ Million)

Table 30 Middle East &amp; Africa Onychomycosis Treatment Market Value, By Treatment Type, 2022-2031(US$ Million)

Table 31 Middle East &amp; Africa Onychomycosis Treatment Market Value, By End User, 2022-2031(US$ Million)

Table 32 Bausch Health Companies Inc: Overview

Table 33 Bausch Health Companies Inc: Product Portfolio

Table 34 Bausch Health Companies Inc: Key Developments

Table 35 Novartis AG: Overview

Table 36 Novartis AG: Product Portfolio

Table 37 Novartis AG: Key Developments

Table 38 Pfizer, Inc: Overview

Table 39 Pfizer, Inc: Product Portfolio

Table 40 Pfizer, Inc: Key Developments

Table 41 Moberg Pharma AB: Overview

Table 42 Moberg Pharma AB: Product Portfolio

Table 43 Moberg Pharma AB: Key Developments

Table 44 Bayer AG: Overview

Table 45 Bayer AG: Product Portfolio

Table 46 Bayer AG: Key Developments

Table 47 Dr. Reddy&rsquo;s Laboratories Ltd: Overview

Table 48 Dr. Reddy&rsquo;s Laboratories Ltd: Product Portfolio

Table 49 Dr. Reddy&rsquo;s Laboratories Ltd: Key Developments

Table 50 Gladerma: Overview

Table 51 Gladerma: Product Portfolio

Table 52 Gladerma: Key Developments

Table 53 Medimetriks Pharmaceuticals, Inc: Overview

Table 54 Medimetriks Pharmaceuticals, Inc: Product Portfolio

Table 55 Medimetriks Pharmaceuticals, Inc: Key Developments

Table 56 Kaken Pharmaceuticals: Overview

Table 57 Kaken Pharmaceuticals: Product Portfolio

Table 58 Kaken Pharmaceuticals: Key Developments

Table 59 Hahn Medical Systems: Overview

Table 60 Hahn Medical Systems: Product Portfolio

Table 61 Hahn Medical Systems: Key Developments

List of Figures

Figure 1 Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 2 Global Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 3 Global Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 4 Global Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 5 Global Onychomycosis Treatment Market Share, By Region, 2022 &amp; 2031(%)

Figure 6 Global Onychomycosis Treatment Market Y-o-Y Growth, By Type, 2022-2031(%)

Figure 7 Distal Subungual Onychomycosis Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 8 White Superficial Onychomycosis Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 9 Proximal Subungual Onychomycosis Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 10 Candida Onychomycosis Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 11 Total Dystrophic Onychomycosis Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 12 Global Onychomycosis Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2031(%)

Figure 13 Oral therapy Treatment Type in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 14 Topical Therapy Treatment Type in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 15 Photodynamic Therapy Treatment Type in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 16 CiclopiroxNail Lacquers Treatment Type in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 17 Others Treatment Type in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 18 Global Onychomycosis Treatment Market Y-o-Y Growth, By End User, 2022-2031(%)

Figure 19 Hospitals End User in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 20 Clinics End User in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 21 Others End User in Global Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 22 Global Onychomycosis Treatment Market Y-o-Y Growth, By Region, 2022-2031(%)

Figure 23 North America Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 24 Asia-Pacific Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 25 Europe Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 26 South America Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 27 Middle East and Africa Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 28 North America Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 29 North America Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 30 North America Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 31 North America Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 32 North America Onychomycosis Treatment Market Share, By Country, 2022 &amp; 2031(%)

Figure 33 South America Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 34 South America Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 35 South America Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 36 South America Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 37 South America Onychomycosis Treatment Market Share, By Country, 2022 &amp; 2031(%)

Figure 38 Europe Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 39 Europe Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 40 Europe Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 41 Europe Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 42 Europe Onychomycosis Treatment Market Share, By Country, 2022 &amp; 2031(%)

Figure 43 Asia-Pacific Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 44 Asia-Pacific Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 45 Asia-Pacific Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 46 Asia-Pacific Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 47 Asia-Pacific Onychomycosis Treatment Market Share, By Country, 2022 &amp; 2031(%)

Figure 48 Middle East &amp; Africa Onychomycosis Treatment Market Value, 2022-2031(US$ Million)

Figure 49 Middle East &amp; Africa Onychomycosis Treatment Market Share, By Type, 2022 &amp; 2031(%)

Figure 50 Middle East &amp; Africa Onychomycosis Treatment Market Share, By Treatment Type, 2022 &amp; 2031(%)

Figure 51 Middle East &amp; Africa Onychomycosis Treatment Market Share, By End User, 2022 &amp; 2031(%)

Figure 52 Bausch Health Companies Inc: Financials

Figure 53 Novartis AG: Financials

Figure 54 Pfizer, Inc: Financials

Figure 55 Moberg Pharma AB: Financials

Figure 56 Bayer AG: Financials

Figure 57 Dr. Reddy&rsquo;s Laboratories Ltd: Financials

Figure 58 Gladerma: Financials

Figure 59 Medimetriks Pharmaceuticals, Inc: Financials

Figure 60 Kaken Pharmaceuticals: Financials

Figure 61 Hahn Medical Systems: Financials

Onychomycosis Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Dermatophytic Onychomycosis Therapeutics (DOT) Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2024 January 29

Starting from